Free Trial

BioXcel Therapeutics (BTAI) Stock Forecast & Price Target

BioXcel Therapeutics logo
$3.52 -0.06 (-1.68%)
Closing price 09/10/2025 04:00 PM Eastern
Extended Trading
$3.58 +0.06 (+1.70%)
As of 06:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioXcel Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
1
Buy
4

Based on 6 Wall Street analysts who have issued ratings for BioXcel Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a sell rating, 1 has given a hold rating, 3 have given a buy rating, and 1 has given a strong buy rating for BTAI.

Consensus Price Target

$39.75
1,029.26% Upside
According to the 6 analysts' twelve-month price targets for BioXcel Therapeutics, the average price target is $39.75. The highest price target for BTAI is $80.00, while the lowest price target for BTAI is $4.00. The average price target represents a forecasted upside of 1,029.26% from the current price of $3.52.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for BTAI and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioXcel Therapeutics and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BTAI Analyst Ratings Over Time

TypeCurrent Forecast
9/11/24 to 9/11/25
1 Month Ago
8/12/24 to 8/12/25
3 Months Ago
6/13/24 to 6/13/25
1 Year Ago
9/12/23 to 9/11/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$39.75$49.25$42.60$88.00
Forecasted Upside1,029.26% Upside624.26% Upside2,630.77% Upside901.82% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

BTAI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BTAI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioXcel Therapeutics Stock vs. The Competition

TypeBioXcel TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside1,029.26% Upside17,074.37% Upside11.30% Upside
News Sentiment Rating
Positive News

See Recent BTAI News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/28/2025HC Wainwright
1 of 5 stars
Reiterated RatingBuy$10.00+152.52%
8/26/2025Zacks Research
0 of 5 stars
 DowngradeStrong-BuyHold
3/19/2025RODMAN&RENSHAW
0 of 5 stars
E. Piros
Not Rated
UpgradeStrong-Buy
3/19/2025Rodman & Renshaw
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$65.00+2,498.95%
1/7/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuyUnderperform$112.00 ➝ $4.00-47.72%
1/6/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$112.00 ➝ $80.00+1,107.73%
8/9/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetNeutral$56.00 ➝ $16.00+32.78%
10/4/2023Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:26 AM ET.


BTAI Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for BioXcel Therapeutics is $39.75, with a high forecast of $80.00 and a low forecast of $4.00.

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There is currently 1 sell rating, 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BTAI shares.

According to analysts, BioXcel Therapeutics's stock has a predicted upside of 1,029.26% based on their 12-month stock forecasts.

Over the previous 90 days, BioXcel Therapeutics's stock had 1 downgrade by analysts.

BioXcel Therapeutics has been rated by research analysts at HC Wainwright, and Zacks Research in the past 90 days.

Analysts like BioXcel Therapeutics less than other "medical" companies. The consensus rating score for BioXcel Therapeutics is 2.67 while the average consensus rating score for "medical" companies is 2.78. Learn more on how BTAI compares to other companies.


This page (NASDAQ:BTAI) was last updated on 9/11/2025 by MarketBeat.com Staff
From Our Partners